Movatterモバイル変換


[0]ホーム

URL:


PE38997A1 - TACHYCININE ANTAGONIST - Google Patents

TACHYCININE ANTAGONIST

Info

Publication number
PE38997A1
PE38997A1PE1995286859APE28685995APE38997A1PE 38997 A1PE38997 A1PE 38997A1PE 1995286859 APE1995286859 APE 1995286859APE 28685995 APE28685995 APE 28685995APE 38997 A1PE38997 A1PE 38997A1
Authority
PE
Peru
Prior art keywords
phenyl
compound
formula
disstituted
carbamoil
Prior art date
Application number
PE1995286859A
Other languages
Spanish (es)
Inventor
Soo Young Ko
Christopher Walpole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9Aexternal-prioritypatent/GB9425085D0/en
Priority claimed from GBGB9426016.3Aexternal-prioritypatent/GB9426016D0/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of PE38997A1publicationCriticalpatent/PE38997A1/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

SE REFIERE AL COMPUESTO ANALGESICO Y ANTIINFLAMATORIO DE FORMULA I DONDE: R1 ES FENILO MONO O DISUSTITUIDO POR UNO O DOS MIEMBROS SELECCIONADOS DE HALOGENO, NITRO, CIANO ENTRE OTROS; n ES CERO O UNO; X1 ES OXIGENO, AZUFRE o =NCN; X2 Y X3 SON CADA UNO INDEPENDIENTEMENTE OXIGENO O AZUFRE; R2 ES HIDROGENO O METILO; R3 ES FENILO, FENILO SUSTITUIDO CON HALO, 2-NAFTILO, ENTRE OTROS; Z ES -N(CH3) o -CH2-; R4 ES FENILO, 3,5-BIS(TRIFLUOROMETIL)FENILO O PIRIDILO; R5 ES HIDROGENO, FENILO, 3,5-BIS(TRIFLUOROMETIL)FENILO O PIRIDILO; TAMBIEN SE REFIERE AL PROCESO DE PRODUCCION QUE COMPRENDE LA REACCION DEL COMPUESTO DE FORMULA II DONDE R2, R3, R4 Y R5 YA SE DEFINIERON, CON EL COMPUESTO DE FORMULA R1`-(CH2)n-N=C=X1 EN LA QUE R1' ES FENILO, MONO O DISUSTITUIDO POR UNO O DOS MIEMBROS SELECCIONADOS DEL GRUPO QUE CONSISTE DE HALOGENO, NITRO, CIANO ENTRE OTROS; n Y X1 TIENEN LOS SIGNIFICADOS YA INDICADOS; CUANDO SE REQUIERE, LLEVAR A CABO LA DESPROTECCION DEL COMPUESTO ASI OBTENIDO, EN EL QUE R1' ES FENILO SUSTITUIDO POR HIDROXI PROTEGIDO Y/O HIDROXIMETILO PROTEGIDO Y/O REALIZAR LA TRANSFORMACION DEL COMPUESTO ASI OBTENIDO, EN EL QUE R1 ES FENILO SUSTITUIDO POR METOXICARBONILO, PARA OBTENER EL COMPUESTO CORRESPONDIENTE EN EL QUE R1' ES FENILO SUSTITUIDO POR CARBAMOILO o N-METILCARBAMOILO Y LUEGO LA RECUPERACION DEL COMPUESTOIT REFERS TO THE ANALGESIC AND ANTI-INFLAMMATORY COMPOUND OF FORMULA I WHERE: R1 IS MONO PHENYLUS OR DISSTITUTED BY ONE OR TWO SELECTED MEMBERS OF HALOGEN, NITRO, CIANO AMONG OTHERS; n IS ZERO OR ONE; X1 IS OXYGEN, SULFUR, or = NCN; X2 AND X3 ARE EACH INDEPENDENTLY OXYGEN OR SULFUR; R2 IS HYDROGEN OR METHYL; R3 IS PHENYL, PHENYL SUBSTITUTED WITH HALO, 2-NAPHTHYL, AMONG OTHERS; Z IS -N (CH3) or -CH2-; R4 IS PHENYL, 3,5-BIS (TRIFLUOROMETHYL) PHENYL OR PIRIDYL; R5 IS HYDROGEN, PHENYL, 3,5-BIS (TRIFLUOROMETIL) PHENYL OR PIRIDYL; IT ALSO REFERS TO THE PRODUCTION PROCESS THAT INCLUDES THE REACTION OF THE COMPOUND OF FORMULA II WHERE R2, R3, R4 AND R5 HAVE ALREADY BEEN DEFINED, WITH THE COMPOUND OF FORMULA R1`- (CH2) nN = C = X1 WHERE R1 'IS FENILE, MONKEY OR DISSTITUTED BY ONE OR TWO SELECTED MEMBERS OF THE GROUP THAT CONSISTS OF HALOGEN, NITRO, CIANO AMONG OTHERS; n AND X1 HAVE THE MEANINGS ALREADY INDICATED; WHEN REQUIRED, CARRY OUT THE DEPROTECTION OF THE COMPOUND SO OBTAINED, IN WHICH R1 'IS PHENYL SUBSTITUTED FOR PROTECTED HYDROXY AND / OR HYDROXYMETHYLUM PROTECTED AND / OR PERFORM THE ESOOIL, ENOIL , TO OBTAIN THE CORRESPONDING COMPOUND IN WHICH R1 'IS PHENYL SUBSTITUTED BY CARBAMOIL OR N-METHYL CARBAMOIL AND THEN RECOVERY OF THE COMPOUND

PE1995286859A1994-12-131995-12-11 TACHYCININE ANTAGONISTPE38997A1 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
GBGB9425085.9AGB9425085D0 (en)1994-12-131994-12-13Organic compounds
GBGB9426016.3AGB9426016D0 (en)1994-12-221994-12-22Organic compounds

Publications (1)

Publication NumberPublication Date
PE38997A1true PE38997A1 (en)1997-10-02

Family

ID=26306161

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PE1995286859APE38997A1 (en)1994-12-131995-12-11 TACHYCININE ANTAGONIST

Country Status (17)

CountryLink
EP (1)EP0797583A1 (en)
JP (1)JPH10511935A (en)
AR (1)AR001332A1 (en)
AU (1)AU4343796A (en)
BR (1)BR9509997A (en)
CA (1)CA2204130A1 (en)
CO (1)CO4700289A1 (en)
CZ (1)CZ179097A3 (en)
FI (1)FI971685L (en)
HU (1)HUT77002A (en)
IL (1)IL116323A0 (en)
NO (1)NO972526L (en)
PE (1)PE38997A1 (en)
PL (1)PL320217A1 (en)
SK (1)SK74697A3 (en)
TR (1)TR199501568A2 (en)
WO (1)WO1996018643A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO1998015277A2 (en)*1996-10-071998-04-16Merck Sharp & Dohme LimitedCns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agents
US6117855A (en)1996-10-072000-09-12Merck Sharp & Dohme Ltd.Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
WO2000048623A1 (en)1999-02-182000-08-24Kaken Pharmaceutical Co., Ltd.Novel amide derivatives as growth hormone secretagogues
US7163949B1 (en)1999-11-032007-01-16Amr Technology, Inc.4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (en)1999-11-032004-07-30Albany Molecular Res IncAryl and heteroaryl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin.
EP1299393A2 (en)2000-07-112003-04-09Bristol-Myers Squibb Pharma Company4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
CN101119969B (en)2004-07-152014-04-09阿尔巴尼分子研究公司 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and their use to block the reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (en)2005-05-172012-04-15Merck Sharp & Dohme CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER
NZ565111A (en)2005-07-152011-10-28Amr Technology IncAryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (en)2005-09-292008-06-02머크 앤드 캄파니 인코포레이티드Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en)2006-02-152006-03-29Angeletti P Ist Richerche BioTherapeutic compounds
WO2008039327A2 (en)2006-09-222008-04-03Merck & Co., Inc.Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)2006-11-012011-09-08Barbara Brooke Jennings-SpringCompounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008084261A1 (en)2007-01-102008-07-17Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SpaAmide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
CN101641099A (en)2007-01-242010-02-03葛兰素集团有限公司Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
AU2008233662B2 (en)2007-04-022012-08-23Msd K.K.Indoledione derivative
JP5501227B2 (en)2007-06-272014-05-21メルク・シャープ・アンド・ドーム・コーポレーション 4-Carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (en)2008-03-032011-05-19タイガー ファーマテック Tyrosine kinase inhibitor
US9156812B2 (en)2008-06-042015-10-13Bristol-Myers Squibb CompanyCrystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (en)2009-04-012012-09-19Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
CN102638982B (en)2009-05-122015-07-08百时美施贵宝公司 (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3, Crystal form of 4-tetrahydroisoquinoline and its use
US9034899B2 (en)2009-05-122015-05-19Albany Molecular Research, Inc.Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
ES2662072T3 (en)2009-05-122018-04-05Albany Molecular Research, Inc. 7 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydroisoquinoline and use thereof
NZ599343A (en)2009-10-142014-05-30Merck Sharp & DohmeSubstituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en)2010-06-242018-10-24Merck Sharp & Dohme Corp.Novel heterocyclic compounds as erk inhibitors
EP2601293B1 (en)2010-08-022017-12-06Sirna Therapeutics, Inc.RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2807307C (en)2010-08-172021-02-09Merck Sharp & Dohme Corp.Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US8883801B2 (en)2010-08-232014-11-11Merck Sharp & Dohme Corp.Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en)2010-09-012015-02-03Merck Sharp & Dohme Corp.Indazole derivatives useful as ERK inhibitors
WO2012036997A1 (en)2010-09-162012-03-22Schering CorporationFused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en)2010-10-292021-01-20Sirna Therapeutics, Inc.Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en)2010-12-212016-05-31Merck Sharp & Dohme Corp.Indazole derivatives useful as ERK inhibitors
JP2014514321A (en)2011-04-212014-06-19メルク・シャープ・アンド・ドーム・コーポレーション Insulin-like growth factor 1 receptor inhibitor
EP2770987B1 (en)2011-10-272018-04-04Merck Sharp & Dohme Corp.Novel compounds that are erk inhibitors
US20150299696A1 (en)2012-05-022015-10-22Sirna Therapeutics, Inc.SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (en)2012-09-282018-07-06Мерк Шарп И Доум Корп.Novel compounds that are erk inhibitors
ME02925B (en)2012-11-282018-04-20Merck Sharp & Dohme COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
MX373639B (en)2012-12-202020-05-04Merck Sharp & Dohme SUBSTITUTED IMIDAZOPYRIDINES AS HUMAN DOUBLE MINUTE 2 INHIBITORS.
US9540377B2 (en)2013-01-302017-01-10Merck Sharp & Dohme Corp.2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en)2013-09-032016-07-07Moderna Therapeutics, Inc.Circular polynucleotides
US10975084B2 (en)2016-10-122021-04-13Merck Sharp & Dohme Corp.KDM5 inhibitors
US10947234B2 (en)2017-11-082021-03-16Merck Sharp & Dohme Corp.PRMT5 inhibitors
WO2019094312A1 (en)2017-11-082019-05-16Merck Sharp & Dohme Corp.Prmt5 inhibitors
WO2020033282A1 (en)2018-08-072020-02-13Merck Sharp & Dohme Corp.Prmt5 inhibitors
MX2021001486A (en)2018-08-072021-07-15Merck Sharp & Dohme LlcPrmt5 inhibitors.
US11981701B2 (en)2018-08-072024-05-14Merck Sharp & Dohme LlcPRMT5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5164372A (en)*1989-04-281992-11-17Fujisawa Pharmaceutical Company, Ltd.Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (en)*1991-12-271993-07-27Japan Tobacco IncProline derivative

Also Published As

Publication numberPublication date
SK74697A3 (en)1997-11-05
JPH10511935A (en)1998-11-17
NO972526D0 (en)1997-06-03
WO1996018643A1 (en)1996-06-20
BR9509997A (en)1997-12-30
CO4700289A1 (en)1998-12-29
AR001332A1 (en)1997-10-22
IL116323A0 (en)1996-03-31
FI971685A0 (en)1997-04-18
TR199501568A2 (en)1996-07-21
CZ179097A3 (en)1997-10-15
HUT77002A (en)1998-03-02
EP0797583A1 (en)1997-10-01
CA2204130A1 (en)1996-06-20
PL320217A1 (en)1997-09-15
FI971685A7 (en)1997-08-13
NO972526L (en)1997-06-03
MX9703957A (en)1997-09-30
AU4343796A (en)1996-07-03
FI971685L (en)1997-08-13

Similar Documents

PublicationPublication DateTitle
PE38997A1 (en) TACHYCININE ANTAGONIST
PE52396A1 (en) NEW COMPOUND THAT CAN MAINTAIN, INCREASE OR RESTORE CELL SENSITIVITY TO THERAPEUTIC OR PROPHYLACTIC AGENTS
ES2059327T3 (en) DERIVATIVES OF TETRAHIDRONAFTALENO AND INDANO, OBTAINING THE SAME AND USE IN PHARMACEUTICAL PREPARATIONS.
ATE89263T1 (en) NAPHTHALINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
HUP0301671A2 (en)4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
PT1075259E (en) NEW FATAL ANALOGS FOR THE TREATMENT OF DIABETES
ES2128629T3 (en) BENCILPIPERIDINE DERIVATIVES WITH HIGH AFFINITY AT AMINO ACID RECEPTOR LINK POINTS.
DE69722027D1 (en) CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
ZA842185B (en)New n-aryl-n'-cycloalkylalkanoyl-piperazine and process for the production thereof
PE58599A1 (en) 2-AMINO-6- (4-PHENOXI-2-SUBSTITUTED) -PIRIDINES SUBSTITUTED
NO983493L (en) New benzimidazole, benzoxazole and benzothiazole compounds, process for their preparation and pharmaceutical compositions containing such
ES2111930T3 (en) AMP ACID ANTAGONISTS AND TREATMENT PROCEDURES WITH THE HELP OF THESE.
PE120099A1 (en) NEW 3,4-DIARYLTIAZOLINE-2-ONA OR 2-THIONA DERIVATIVES, THEIR PREPARATION METHODS AND THERAPEUTIC USE
DE3583872D1 (en) DIHYDROPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHOD FOR THE PRODUCTION OF THESE COMPOSITIONS.
ES8307774A1 (en)Diamino isothiazole -1-oxides and -1,1-dioxides as gastric secretion inhibitors.
FR2713085B1 (en) Dye composition containing sulfur p-phenylenediamines and corresponding dyeing processes, new sulfur p-phenylenediamines and process for their preparation.
ATE80390T1 (en) BARBITURAL ACID COMPOUNDS, PHOTORESISTS CONTAINING THEM AND PROCESS FOR THEIR MANUFACTURE.
ATE178059T1 (en) 4-PHENYLCARBAMOYL-3-ISOXAZOLECARBOXYLIC ACID DERIVATIVE WITH ANTI-INFLAMMATORY ACTIVITY
NO873564L (en) NEW TYRONINE DERIVATIVES.
ATE20066T1 (en) NEW BASIC SUBSTITUTED 4-PHENYL-4,5,6,7TETRAHYDROTHIENO-(2,3-C)PYRIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2145480T3 (en) CARBAMOILCARBOXILIC ACID AMIDES.
ATE162191T1 (en) AZANORADAMANTANE
KR930019639A (en) Iminocarboxylic acid derivative having allergy / asthma treatment effect and preparation method thereof
KR870003082A (en) Method for preparing oxetane and thiethane derivatives
ES2040744T3 (en) A PROCEDURE FOR PREPARING 1,2,4-TRIAZINONE DERIVATIVES.

Legal Events

DateCodeTitleDescription
FGGrant, registration
FDApplication declared void or lapsed

[8]ページ先頭

©2009-2025 Movatter.jp